See more : New York Mortgage Trust, Inc. (NYMTN) Income Statement Analysis – Financial Results
Complete financial analysis of CytoTools AG (T5O.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CytoTools AG, a leading company in the Biotechnology industry within the Healthcare sector.
- MODULEX CONSTRUCTION TECHNOLOG (MODULEX.BO) Income Statement Analysis – Financial Results
- TriSalus Life Sciences, Inc. (TLSI) Income Statement Analysis – Financial Results
- RioCan Real Estate Investment Trust (RIOCF) Income Statement Analysis – Financial Results
- Aoshikang Technology Co., Ltd. (002913.SZ) Income Statement Analysis – Financial Results
- Adeshwar Meditex Limited (ADESHWAR.BO) Income Statement Analysis – Financial Results
CytoTools AG (T5O.DE)
About CytoTools AG
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.40K | 12.23K | 44.63K | 36.00K | 36.18K | 1.01K | 89.82K | 0.00 | 0.00 | 300.49K | 50.00K | 50.00K | 50.00K | 50.00K | 50.00K |
| Cost of Revenue | 0.00 | 0.00 | 540.65K | 748.31K | 309.95K | 426.13K | 392.52K | 297.08K | 415.30K | 302.12K | 520.65K | 289.68K | 0.00 | 75.74K | 31.73K |
| Gross Profit | 17.40K | 12.23K | -496.02K | -712.31K | -273.77K | -425.11K | -302.70K | -297.08K | -415.30K | -1.63K | -470.65K | -239.68K | 50.00K | -25.74K | 18.27K |
| Gross Profit Ratio | 100.00% | 100.00% | -1,111.51% | -1,978.64% | -756.67% | -42,048.86% | -337.01% | 0.00% | 0.00% | -0.54% | -941.29% | -479.36% | 100.00% | -51.49% | 36.54% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 283.00K | 177.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.01K | 27.96K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 164.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.00K | 22.96K |
| SG&A | 7.71K | 3.54K | 549.32K | 283.00K | 341.95K | 438.36K | 325.64K | 321.43K | 439.04K | 323.68K | 535.40K | 310.23K | 0.00 | 56.01K | 50.92K |
| Other Expenses | 9.69K | 40.00 | -31.98K | 3.67K | 840.00 | 1.36K | 3.18K | -340.00 | -500.00 | 0.00 | 0.00 | 0.00 | 0.00 | -30.00K | -211.21K |
| Operating Expenses | 17.40K | 835.23K | 1.57M | 1.13M | 901.02K | 799.75K | 714.45K | 681.37K | 889.24K | 1.04M | 688.31K | 452.13K | 889.06K | 613.17K | 498.04K |
| Cost & Expenses | 17.40K | 835.23K | 1.57M | 1.87M | 1.21M | 1.23M | 1.11M | 978.45K | 1.30M | 1.34M | 1.21M | 741.81K | 889.06K | 688.91K | 529.78K |
| Interest Income | 15.06K | 34.81K | 1.94K | 164.54 | 99.72K | 53.01K | 11.43K | 104.17 | 1.12K | 10.02K | 24.12K | 37.03K | 18.37K | 6.94K | 13.91K |
| Interest Expense | 0.00 | 41.65K | 2.12K | 776.24 | 99.72K | 251.09K | 58.24K | 0.00 | 71.43 | 100.00 | 133.00 | 236.17 | 1.13K | 200.00 | 476.41 |
| Depreciation & Amortization | 20.20M | 5.25K | 59.37K | 20.77K | 18.96K | 29.98K | 36.45K | 19.11K | 13.00K | 14.00K | 13.00K | 14.00K | 13.00K | 35.00K | 218.00K |
| EBITDA | -801.09K | -782.94K | 1.02M | -1.82M | -1.16M | -1.14M | -969.71K | -959.68K | -1.29M | -1.02M | -1.12M | -640.35K | -807.63K | -626.97K | -459.07K |
| EBITDA Ratio | -4,602.93% | -6,400.20% | 2,289.75% | -5,046.94% | -3,194.47% | -112,761.61% | -1,080.05% | 0.00% | 0.00% | -338.08% | -2,243.47% | -1,280.70% | -1,615.26% | -1,253.95% | -918.15% |
| Operating Income | -21.81M | -823.00K | -1.57M | -1.84M | -1.16M | -1.22M | -1.02M | -978.78K | -1.31M | -1.04M | -1.13M | -655.01K | -839.06K | -661.97K | -677.07K |
| Operating Income Ratio | -125,287.31% | -6,727.67% | -3,516.49% | -5,107.18% | -3,194.60% | -121,019.39% | -1,132.89% | 0.00% | 0.00% | -346.20% | -2,269.93% | -1,310.02% | -1,678.11% | -1,323.95% | -1,354.15% |
| Total Other Income/Expenses | 855.87K | -6.84K | -2.45M | -184.77 | -118.68K | -197.61K | -47.23K | 441.44 | 1.54K | 5.59K | 0.00 | -1.00 | 17.24K | -23.26K | -197.77K |
| Income Before Tax | -20.95M | -829.84K | -4.02M | -1.84M | -1.27M | -1.42M | -1.06M | -978.34K | -1.30M | -1.03M | -1.13M | -655.01K | -821.81K | -662.17K | -677.55K |
| Income Before Tax Ratio | -120,369.63% | -6,783.60% | -9,005.12% | -5,107.43% | -3,522.60% | -140,565.14% | -1,185.47% | 0.00% | 0.00% | -344.35% | -2,269.93% | -1,310.02% | -1,643.63% | -1,324.35% | -1,355.10% |
| Income Tax Expense | 0.68 | 34.81K | 40.30K | 429.89 | 424.00 | 474.83 | 418.00 | 339.63 | 496.38 | 418.00 | 126.00 | 397.54 | 697.00 | 456.50 | 357.00 |
| Net Income | -20.95M | -829.84K | -4.06M | -1.84M | -1.27M | -1.42M | -1.07M | -978.68K | -1.30M | -1.04M | -1.14M | -655.41K | -822.51K | -662.63K | -677.91K |
| Net Income Ratio | -120,369.63% | -6,783.60% | -9,095.43% | -5,108.88% | -3,523.78% | -140,612.11% | -1,185.94% | 0.00% | 0.00% | -344.48% | -2,270.18% | -1,310.82% | -1,645.02% | -1,325.26% | -1,355.81% |
| EPS | -4.08 | -0.17 | -1.02 | -0.46 | -0.35 | -0.51 | -0.50 | -0.48 | -0.64 | -0.55 | -0.61 | -0.38 | -0.46 | -0.46 | -0.47 |
| EPS Diluted | -4.08 | -0.17 | -1.02 | -0.46 | -0.35 | -0.51 | -0.49 | -0.48 | -0.64 | -0.53 | -0.59 | -0.37 | -0.46 | -0.46 | -0.47 |
| Weighted Avg Shares Out | 5.14M | 4.97M | 3.97M | 3.97M | 3.60M | 2.77M | 2.12M | 2.06M | 2.05M | 1.89M | 1.87M | 1.72M | 1.78M | 1.43M | 0.00 |
| Weighted Avg Shares Out (Dil) | 5.14M | 4.97M | 3.97M | 3.97M | 3.60M | 2.77M | 2.18M | 2.06M | 2.05M | 1.95M | 1.93M | 1.77M | 1.78M | 1.43M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports